Prevention of Meningococcus C Infections
Conditions
Keywords
meningococcus C
Brief summary
Meningococcus C vaccine was first used in France to prevent epidemics. It was a success in Puy-de-Dôme, Landes, Pyrénées Atlantiques and Hautes Pyrénées. Following many European countries, France introduced meningococcus C conjugate vaccine in 2009 but this recommendation was not suffiicently applied (6,6% of the 20-25 years-old were vaccinated in 2015). The situation in France is very different from UK and there is no data on the subject. The vaccination campaign in 2002 in Puy-de-Dôme offers much more detachment, possible comparison between vaccinated and unvaccinated people, among which meningococcus circulation could maintain immunity. This is the reason why we have decided to assess in 2016 the vaccinal and natural immunity among Puy-de-Dôme population.
Detailed description
People were recruited during hospitalisation or consultation of Pediatric, Occupational Medecine, Infectiology departments of Clermont Ferrand Hospital or Health Service of Auvergne's University, from March to September 2016. Doctors gave informations about the study and collected consents before blood tests were done (two tubes of 4,5mL each). Blood tests were daily collected and freezed. Then they were analysed at Meningococcus National Reference Center, in Paris.
Interventions
OTHERMeningococcus C conjugate vaccine
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* \- people from 13 to 39 years old * who received meningococcus C conjugate vaccine in 2002 in Puy-de-Dôme (vaccinated group) or not (unvaccinated group)
Exclusion criteria
* vaccination before or after 2002 containing meningococcus C valence * refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation in 2016 of immunity's level (antibodies) against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme | at day 1 |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the duration (years) of vaccinal immunity | at day 1 |
| Compare vaccinal immunity to possible natural immunity (antibodies level) among unvaccinated people | at day 1 |
| Determine the cutt-off (age) for which vaccinal immunity is still protective (sufficient antibodies level) | at day 1 |
| Adjust results on sociodemographic data (age, sex, city, number of years spent in Puy de Dôme, Auvergne, France and abroad from 2002 to 2016) | at day 1 |
Countries
France
Outcome results
None listed